{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:39:12Z","timestamp":1770338352388,"version":"3.49.0"},"reference-count":21,"publisher":"European Respiratory Society (ERS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2001,7,3]]},"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p>This study compared the safety of formoterol (Oxis\u00ae Turbuhaler\u00ae; 90\u2005\u00b5g delivered dose; 120\u2005\u00b5g metered dose) with terbutaline (Bricanyl\u00ae Turbuhaler\u00ae; 10\u2005mg), in patients with acute bronchoconstriction.<\/jats:p><jats:p>Forty-eight patients (31 females) with a mean age of 45\u2005yrs, were randomized into two parallel groups (double-blind design). Mean baseline forced expiratory volume in one second (FEV<jats:sub>1<\/jats:sub>) was 0.98 L (33% of predicted normal). Study drugs were administered on six occasions during 3\u2005h (formoterol 4.5\u2005\u00b5g or terbutaline 0.5\u2005mg\u00b7inhalation<jats:sup>\u22121<\/jats:sup>, 20 inhalations). Patients received intravenous prednisolone after 1.5\u2005h and oxygen during the first 3\u2005h. Pulse rate, serum potassium, 12-lead electrocardiogram (ECG), Holter ECG, arterial blood gases and FEV<jats:sub>1<\/jats:sub>were assessed during 12\u2005h after the first dose.<\/jats:p><jats:p>Four patients (one formoterol, three terbutaline) discontinued. The 12-h mean values of serum potassium decreased from 4.02 to 3.89\u2005mmol\u00b7L<jats:sup>\u22121<\/jats:sup>for formoterol and from 4.22 to 3.76\u2005mmol\u00b7L<jats:sup>\u22121<\/jats:sup>for terbutaline. Mean 12-h pulse rate was significantly (p&lt;0.01) higher in the terbutaline group (101.7 beats per minute (bpm)) than in the formoterol group (93.5 bpm). No individual patient value was considered clinically important or alarming. FEV<jats:sub>1<\/jats:sub>improved in both groups but with no statistically significant difference between treatments.<\/jats:p><jats:p>Oxis\u00ae Turbuhaler\u00ae (90\u2005\u00b5g) was at least as safe and well tolerated as terbutaline (110\u2005mg) in patients with acute bronchoconstriction.<\/jats:p>","DOI":"10.1183\/09031936.01.00251901","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:36:48Z","timestamp":1027773408000},"page":"928-934","source":"Crossref","is-referenced-by-count":60,"title":["Safety of formoterol Turbuhaler\u00ae at cumulative dose of 90\u2005\u00b5g in patients with acute bronchial obstruction"],"prefix":"10.1183","volume":"18","author":[{"given":"J.","family":"Malolepszy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"B\u00f6sz\u00f6rm\u00e9nyi Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Selroos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Brander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2001,12,1]]},"reference":[{"key":"2024101809004610000_18.6.928.1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/thx.52.2008.S1.5","volume":"52","year":"1997","journal-title":"Thorax"},{"key":"2024101809004610000_18.6.928.2","unstructured":"National Heart, Lung and Blood Institute, Bethesda, USA. Expert Panel Report II; Guidelines for the Diagnosis and Management of Asthma, 1997."},{"key":"2024101809004610000_18.6.928.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711133372001"},{"key":"2024101809004610000_18.6.928.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92996-3"},{"key":"2024101809004610000_18.6.928.5","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.5.8630590"},{"key":"2024101809004610000_18.6.928.6","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90796-8"},{"key":"2024101809004610000_18.6.928.7","unstructured":"Reed CE. Asthma. In: Kaplan AP, ed. Allergy. Churchill Livingstone, 1985; pp.\u2005367\u2013\u2013409."},{"key":"2024101809004610000_18.6.928.8","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1183\/09031936.93.04101168","volume":"4","year":"1991","journal-title":"Eur Respir J"},{"key":"2024101809004610000_18.6.928.9","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.6.535"},{"key":"2024101809004610000_18.6.928.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90348-1"},{"key":"2024101809004610000_18.6.928.11","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2000.0788"},{"key":"2024101809004610000_18.6.928.12","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000160"},{"key":"2024101809004610000_18.6.928.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12030573"},{"key":"2024101809004610000_18.6.928.14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.105.3.697","volume":"105","year":"1994","journal-title":"Chest"},{"key":"2024101809004610000_18.6.928.15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-0736(84)80074-6","volume":"17","year":"1984","journal-title":"J Electrocardiol"},{"key":"2024101809004610000_18.6.928.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10112489"},{"key":"2024101809004610000_18.6.928.17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.6.1367"},{"key":"2024101809004610000_18.6.928.18","first-page":"A590","volume":"163","year":"2001","journal-title":"Am Respir Crit Care Med"},{"key":"2024101809004610000_18.6.928.19","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.13e10.x"},{"key":"2024101809004610000_18.6.928.20","doi-asserted-by":"crossref","unstructured":"Vilsvik JS, Ankerst J, Palmqvist M, Persson G, Schaanning J, Johansson \u00c5. Duration of protection of formoterol against exercise-induced bronchoconstriction during regular treatment with formoterol Turbuhaler bid in adult asthmatics. Respir Med 2001; (in press).","DOI":"10.1053\/rmed.2001.1074"},{"key":"2024101809004610000_18.6.928.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03611-4"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.01.00251901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:44:35Z","timestamp":1740375875000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.01.00251901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2001,12,1]]},"published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1183\/09031936.01.00251901"],"URL":"https:\/\/doi.org\/10.1183\/09031936.01.00251901","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}